Clinical Trials - October 8, 2014
Vivolux gets FDA clearance for clinical study
Swedish pharmaceutical company Vivolux has received clearance from the FDA to proceed with the drug candidate VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. The clinical study will be conducted in collaboration with the Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute at Harvard Medical School. This first study is […]
Clinical Trials - April 15, 2014
Vivolux gets green light on cancer study
The Swedish drug discovery company has announced that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company’s drug projects, recently published in the journal Nature Communications. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization – areas that cannot […]
